PREMIER BIOMEDICAL INC: 10-Q filed 2013-11-12
What PREMIER BIOMEDICAL INC reported in its quarterly report filed 2013-11-12 (fiscal Q3 2013): 23 published measures, 76 facts as tagged in accession 0001477932-13-005297.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-11-12
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001477932-13-005297 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PREMIER BIOMEDICAL INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 77,827 | USD | |
| At 2012-12-31 | 43,395 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -102,302 | USD | |
| At 2012-12-31 | -75,766 | USD | |
| At 2011-12-31 | 30,224 | USD | |
| At 2010-12-31 | 12,761 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-12-31 | 40,284 | USD | |
| At 2011-12-31 | 26,264 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -1,033,310 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -3,879,406 | USD | 273 |
| 2010-05-10 to 2013-09-30 | -5,707,447 | USD | 1240 |
| 2012-01-01 to 2012-12-31 | -1,714,023 | USD | 366 |
| 2012-07-01 to 2012-09-30 | -58,545 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -112,554 | USD | 274 |
| 2011-01-01 to 2011-12-31 | -111,862 | USD | 365 |
| 2010-05-10 to 2010-12-31 | -2,156 | USD | 236 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -296,772 | USD | 273 |
| 2010-05-10 to 2013-09-30 | -519,469 | USD | 1240 |
| 2012-01-01 to 2012-09-30 | -72,770 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 331,620 | USD | 273 |
| 2010-05-10 to 2013-09-30 | 611,195 | USD | 1240 |
| 2012-01-01 to 2012-09-30 | 128,650 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -1,414 | USD | 273 |
| 2010-05-10 to 2013-09-30 | -18,008 | USD | 1240 |
| 2012-01-01 to 2012-09-30 | -8,699 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -5,787,370 | USD | |
| At 2012-12-31 | -1,828,041 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,922 | USD | |
| At 2012-12-31 | 3,042 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 3,257,950 | USD | 273 |
| 2012-01-01 to 2012-09-30 | 9,728 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -1,025,266 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -3,870,882 | USD | 273 |
| 2010-05-10 to 2013-09-30 | -5,698,108 | USD | 1240 |
| 2012-07-01 to 2012-09-30 | -58,306 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -112,169 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 73,905 | USD | |
| At 2012-12-31 | 40,353 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 8,044 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 8,524 | USD | 273 |
| 2010-05-10 to 2013-09-30 | 9,339 | USD | 1240 |
| 2012-07-01 to 2012-09-30 | 239 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 385 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 180,129 | USD | |
| At 2012-12-31 | 119,161 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 98,954 | USD | |
| At 2012-12-31 | 88,598 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 1,025,266 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 3,870,882 | USD | 273 |
| 2010-05-10 to 2013-09-30 | 5,698,108 | USD | 1240 |
| 2012-07-01 to 2012-09-30 | 58,306 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 112,169 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 58,473 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 180,213 | USD | 273 |
| 2010-05-10 to 2013-09-30 | 258,617 | USD | 1240 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 17,211,679 | shares | |
| At 2012-12-31 | 12,374,479 | shares |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -3,879,406 | USD | 273 |
| 2010-05-10 to 2013-09-30 | -5,707,447 | USD | 1240 |
| 2012-01-01 to 2012-09-30 | -112,554 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 666,936 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 2,994,164 | USD | 273 |
| 2010-05-10 to 2013-09-30 | 3,050,331 | USD | 1240 |
| 2012-07-01 to 2012-09-30 | 17,265 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 30,342 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 534 | USD | 273 |
| 2010-05-10 to 2013-09-30 | 735 | USD | 1240 |
| 2012-01-01 to 2012-09-30 | 60 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -8,044 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -8,524 | USD | 273 |
| 2010-05-10 to 2013-09-30 | -9,339 | USD | 1240 |
| 2012-07-01 to 2012-09-30 | -239 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -385 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 10,356 | USD | 273 |
| 2010-05-10 to 2013-09-30 | 98,954 | USD | 1240 |
| 2012-01-01 to 2012-09-30 | 28,134 | USD | 274 |
Inspect the source
- Entity
- PREMIER BIOMEDICAL INC / CIK 0001515740
- Captured
- SEC response SHA-256
45da45366bbc272d562b9d509d686e37f5bc6c1ad07c4e9befadf38713a343d8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001515740.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))